Generic Name and Formulations:
Atovaquone 750mg/5mL; oral susp; citrus flavor.
Indications for MEPRON:
Treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in patients intolerant to trimethoprim/sulfamethoxazole (TMP/SMX). Prevention of PCP in patients intolerant to TMP/SMX.
Limitations Of use:
Treatment of more severe PCP has not been studied. Mepron's efficacy has not been studied in those who are failing therapy with TMP/SMX.
Take with food. ≥13yrs: Treatment: 750mg twice daily for 21 days. Prophylaxis: 1500mg once daily.
<13yrs: not established.
GI disorders or inability to take with food. Monitor in severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant rifampin or rifabutin: not recommended. Antagonized by tetracycline; caution and monitor if use is needed. May be antagonized by metoclopramide (use only if other antiemetics are not available). Antagonizes indinavir; caution and monitor if use is needed.
Diarrhea, rash, headache, nausea, fever, rhinitis, vomiting, sweating, flu syndrome, sinusitis, pruritus, insomnia, depression, myalgia.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D